drugset / Trial / NCT00272792

Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet

NCT00272792

Phase 3 Completed 45 enrolled BioMarin Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this trial is to evaluate the ability of Phenoptin to increase phenylalanine (phe) tolerance in children with phenylketonuria who are following a phe-restricted diet.

Timeline

Start
2006-02
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject sapropterin Unknown 20 mg/kg Oral

Indications